PERMETHRIN | A076369 | PADAGIS ISRAEL PHARMACEUTICALS LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consultant Services, Inc. FDA-2019-P-3809 · 3 docket documents Lachman Consultant Services, Inc. filed this petition under section 505(j) of the FDC Act requesting that the FDA designate either Permethrin Cream 5% ANDA 074806 held by Actavis Laboratories, Inc. or Permethrin Cream 5% ANDA 076369 held by Perrigo Israel Pharmaceuticals, Ltd. as the new Reference S | 505(q) | 2019-08-13 | Partially Denied | Lachman Consultant Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.2313
per gm
Lowest NADAC/Unit
$0.2313
per gm
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 45802026937PERMETHRIN 5% CREAM | $0.2313 | GM | Generic | — | 2026-06-17 |
| 16714089701PERMETHRIN 5% CREAM | $0.2313 | GM | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.